Promethera Biosciences dosed the first patient in a phase 2a clinical study of HepaStem for patients with late stage nonalcoholic steatohepatitis, according to a press release.
The open-label study will evaluate safety and preliminary efficacy of HepaStem, a novel allogenic cell-based therapy for severe liver diseases including cirrhosis and pre-cirrhosis NASH.
“Today’s announcement has special significance for our company as NASH is increasingly going to be a significant value driver for our company,” John Tchelingerian, PhD, president and CEO of Promethera, said in the

Source link